



Cross-sectional Study

Correlations between comorbidities, chest x-ray findings, and C-Reactive protein level in patients with COVID-19



Muhammad Fachri^a, Mochammad Hatta^{b,*}, Evelin Widowati^a, Risky Akaputra^a, Ressay Dwiyantri^{c,e}, Ahmad Syukri^{b,d}, Ade Rifka Junita^{b,d}, Andini Febrianti^e, Muhammad Reza Primaguna^f

^a Department of Pulmonology and Respiratory Medicine, Faculty of Medicine and Health, Universitas Muhammadiyah, Jakarta, Indonesia

^b Molecular Biology and Immunology Laboratory, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

^c Department of Medical Microbiology, Faculty of Medicine, Tadulako University, Palu, Indonesia

^d Postgraduate School, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

^e Department of Forensic and Medicolegal, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

^f Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

ARTICLE INFO

Keywords:
Comorbidity
COVID-19
Chest X-ray
C-reactive protein

ABSTRACT

Background: Patients with comorbidities have an increased risk for severe coronavirus disease (COVID-19) symptoms, including abnormal inflammation. Chest X-rays and C-reactive protein (CRP) level are frequently used to evaluate the severity of inflammation. The aim of this study was to investigate the correlation between comorbidities, chest X-ray findings, and CRP level in patients with COVID-19.

Materials and methods: This was a cross-sectional, analytic, observational study performed using a quantitative approach. The study population included in patients with confirmed COVID-19. Secondary data from the medical records of the patients were analysed to determine the correlations between comorbidities, chest X-rays, and CRP level.

Results: The data of 167 patients (87 [52.1%] females and 80 [47.9%] males) were evaluated. Regarding comorbidities, 86 (51.5%) patients had hypertension, 66 (39.5%) had diabetes mellitus, and 17 (10.2%) had dyspepsia. Chest X-rays showed that 144 (86.2%) patients had pneumonia, whereas 23 (13.8%) did not. A total of 143 (85.6%) patients showed increased CRP levels, whereas 24 (14.4%) did not show any increase. Patients who showed pneumonia on chest X-rays tended to have increased CRP levels. The results also showed that chest X-ray findings were correlated with CRP level. Diabetes mellitus and hypertension were significantly correlated with CRP level ($p = 0.05$), whereas dyspepsia did not show a significant relationship with CRP level ($p > 0.05$). Patients with hypertension had a 2.709-fold risk of having increased CRP level compared with patients without hypertension. Patients with pneumonia had a 2.953-fold increased risk for increased CRP level compared to those without pneumonia.

Conclusion: Hypertension and diabetes mellitus are significantly correlated with CRP level. Chest X-ray finding is also significantly correlated with CRP level.

1. Introduction

The coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first case of this viral pneumonia of unknown aetiology was reported on December 12, 2019, in Wuhan, China [1]. SARS-CoV-2 can

be transmitted through contact and droplets, which spread during coughing or sneezing [2]. The incubation period for COVID-19 is about 3–14 days. In this phase, the patient is asymptomatic and leukocyte and lymphocyte counts are still within the normal threshold or are slightly decreased. In the next phase, the virus spreads through the bloodstream and mild symptoms generally start to appear. A second wave of

* Corresponding author.

E-mail addresses: dr.muhammadfachri@gmail.com (M. Fachri), hattaram@yahoo.com (M. Hatta), evelinwidowati@yahoo.co.id (E. Widowati), artupaka@gmail.com (R. Akaputra), ressy_chan@yahoo.co.id (R. Dwiyantri), sukri2901@gmail.com (A. Syukri), junitarifkade@yahoo.com (A.R. Junita), andinifebrianti@gmail.com (A. Febrianti), rezzprima@yahoo.com (M.R. Primaguna).

<https://doi.org/10.1016/j.amsu.2022.103553>

Received 17 February 2022; Received in revised form 26 March 2022; Accepted 26 March 2022

Available online 1 April 2022

2049-0801/© 2022 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

symptoms occurs 4–7 days after the initial symptoms appear. The patient has a fever and shows shortness of breath, lesions in the lungs worsen, and lymphocyte count decreases. Increased levels of inflammatory biomarkers and hypercoagulation are noted in this stage as well [3,4]. The hallmark of severe COVID-19 is the presence of a systemic inflammatory response, and most hospitalised patients with COVID-19 show abnormal inflammation [5]. Evaluation of the levels of inflammation markers, such as C-reactive protein (CRP) and interleukin-6 (IL-6), aids the management of patients with COVID-19 [6]. CRP, which is a protein produced by the liver, is as an early marker of inflammation and an important marker of severe COVID-19 [7,8].

A person with comorbid conditions has increased susceptibility to infection by SARS-CoV-2. Several studies have shown that regarding confirmed COVID-19, people with comorbidities, such as the elderly, have a higher risk of experiencing severe and fatal symptoms than those without comorbidities. The most common comorbidities recorded among patients with COVID-19 are hypertension, diabetes mellitus, heart disease, and chronic obstructive pulmonary disease [9,10].

Accurate diagnosis of COVID-19 is important and can control the spread of the disease. Screening and diagnosis of COVID-19 include laboratory and radiological examinations. Chest radiography is a common radiological examination modality. Pulmonary abnormalities caused by COVID-19 can be monitored on a chest radiograph [11]. According to Baj et al. the course of COVID-19 and the classification of its severity can be determined by imaging and evaluating each stage on chest radiographs [12]. Therefore, the aim of this study was to determine the relationship between comorbidities, chest X-ray findings, and CRP level values in hospitalised patients with confirmed COVID-19.

2. Materials and Methods

This study uses analytical observation and the research design used is cross sectional by taking secondary data from the medical records of inpatients with COVID-19. The study population included in patients with confirmed COVID-19 at the Jakarta Islamic Hospital, Sukapura, from August 2020 to August 2021. This study was performed according to the STROCSS criteria and has been registered at <https://www.researchregistry.com> [13]. This research was submitted to the ethics committee of the Faculty of Medicine and Health, Universitas Muhammadiyah Jakarta, Jakarta, Indonesia (No. 185/PE/KE/FKK-UMJ/X/2021) for approval. Written informed consent was obtained from all participants.

3. Results

The baseline characteristics of the inpatients with confirmed COVID-19 at Jakarta Islamic Hospital, Sukapura are outlined in Table 1. A total of 167 patients, including 87 (52.1%) females and 80 (47.9%) males, were included in this study. Of these, 124 (74.3%) patients were aged <60 years old (youngest patient, 8 years old), whereas 43 (25.7%) were aged ≥60 years old (oldest patient, 90 years old). Regarding employment status, 93 (55.7%) patients were employed and 74 (44.3%) were unemployed.

Table 1
Characteristics of hospitalised patients with confirmed COVID-19.

Characteristics	Total (n)	Percentage (%)
Age		
<60 years	124	74,3
≥60 years	43	25,7
Gender		
Male	80	47,9
Female	87	52,1
Employment status		
Employed	93	55,7
Unemployed	74	44,3

Table 2 shows the comorbidities of the included inpatients. Hypertension was the common comorbidity (86 [51.5%] patients), followed by diabetes mellitus (66 [39.5%] patients) and dyspepsia (17 [10.2%] patients).

A total of 144 (86.2%) patients showed pneumonia on their chest X-rays, whereas 23 (13.8%) did not (Table 3). The patients without pneumonia showed other pulmonary anomalies, including tuberculosis, bronchitis, pleural effusion, pulmonary oedema, and pneumothorax.

Table 4 shows that of the 167 patients analysed, 143 (85.6%) showed an increase in CRP level, whereas 24 (14.4%) did not increase.

The results showed that diabetes mellitus and hypertension were significantly correlated with CRP level ($p = 0.05$). However, dyspepsia was not significantly correlated with CRP level ($p > 0.05$) (Table 5).

Among patients with pneumonia, 128 (76.6%) showed increased CRP levels, whereas 16 (9.6%) did not (Table 6). For patients without pneumonia, 15 (9.0%) showed increased CRP levels, whereas 8 (4.8%) did not. The results also showed that chest X-ray findings were significantly correlated with CRP level.

Multivariate logistic regression analysis showed that patients with hypertension had a 2.709-fold increased risk for elevated CRP level compared with patients without hypertension. Patients with pneumonia had a 2.953-fold increased risk for increased CRP level compared with patients without pneumonia (Table 7).

4. Discussion

The study was conducted to investigate the relationships between comorbidities, chest X-ray findings, and CRP level in hospitalised patients with confirmed COVID-19. The results showed that most of the patients were <60 years old, female, and employed. The findings regarding age and employment status are in line with that of a previous study conducted in Saudi Arabia, which showed that the average age of 99 patients treated for confirmed COVID-19 was 44 years, and that of a study conducted in the United Kingdom, which indicated that most patients with confirmed COVID-19 were employed [14,15]. However, the result regarding sex is not in line with that of a previous study conducted in India, which showed that COVID-19 mostly affects male patients, especially among Asian populations. This is suspected to be related to the fact the prevalence of smoking, which can increase the expression of ACE-2 receptors, is elevated in Asian populations. However, this is only a speculation and further study is needed to validate the theory [10,16].

The spread of COVID-19 has become a global pandemic, which has claimed the lives of more than one million people worldwide. Certain comorbidities are significant risk factors for COVID-19. In the present study, hypertension was the most common comorbid disease among the patients, followed by diabetes mellitus. Diabetes is a chronic inflammatory condition that leads to an increase in the levels of inflammatory markers, such as CRP. The results of the present study showed that diabetes mellitus is significantly correlated with CRP level. This is in accordance with the findings of the study by Koh et al. which revealed that CRP had a mediating proportion of 32.7% of the association of comorbid DM type 2 with severe COVID-19 outcome [17]. The results of

Table 2
Comorbidities of the inpatients with confirmed COVID-19.

Comorbidities	Total (n)	Percentage (%)
Diabetes Mellitus		
Present	66	39,5
Absent	101	60,5
Hypertension		
Present	86	51,5
Absent	81	48,5
Dyspepsia		
Present	17	10,2
Absent	150	89,8

Table 3

Thorax X-ray findings of hospitalised patients with confirmed COVID-19.

Thorax X-Ray	Total (n)	Percentage (%)
Pneumonia	144	86,2
No Pneumonia	23	13,8

Table 4

C-reactive protein levels of the hospitalised patients with confirmed COVID-19.

C-reactive protein level	Total (n)	Percentage (%)
Increased	143	85,6
Not increased	24	14,4

Table 5

Relationship between comorbidities and C-reactive protein level.

Comorbidities		C-reactive protein level		P value
		Increased	Not Increased	
Diabetes mellitus	Present	61	5	0,043
	Absent	82	19	
Hypertension	Present	79	7	0,018
	Absent	64	17	
Dyspepsia	Present	12	5	0,074
	Absent	131	19	

Table 6

Relationship between chest X-Ray findings and C-reactive protein level.

Thorax X-Ray	C-reactive protein level		P value
	Increased	Not Increased	
Pneumonia	128	16	0,007
No Pneumonia	15	8	

Table 7

Results of the multivariate logistic regression analysis.

Variable	Coefficient	P value	Odds ratio
Hypertension	0,997	0,045	2,709
Diabetes mellitus	1,006	0,065	2,736
Chest X-Ray	1,083	0,050	2,953

the present study also showed that hypertension is significantly correlated with CRP level. This is in line the findings a previous Brazilian study.

C-reactive protein is produced by adipocytes and the liver, regulated by IL-1, IL-6, and tumour necrosis factor, and can be measured routinely. Elevated CRP level is an independent risk factor for hypertension; thus, it is often detected in patients with hypertension. Hypertension can worsen if the levels of these inflammatory biomarkers increase because systemic and local inflammatory responses can damage vascular endothelial cells, resulting in a decrease in the levels of nitric oxide and prostaglandins. In addition, increased levels of biomarkers can lead to thickening of the vascular intima that affects the formation of atheroma, resulting in peripheral resistance and reduced vascular reactivity to vasodilators and blood flow velocity, which can exacerbate vascular sclerosis and increase blood pressure [18–26].

Dyspepsia is a relatively common gastrointestinal function disorder. Negative or unpleasant life events, stress, and anxiety are known to trigger and exacerbate irritable bowel syndrome (IBS) and functional dyspepsia (FD). Avoiding physical contact, staying at home, working from home, and reducing the frequency and size of gatherings, are some of the steps that can be taken to control the spread of COVID-19. However, some of these steps are likely to have an impact on mental

health. A study conducted in the United Kingdom showed that physical distancing leads to increased anxiety and depression among the general population. A previous study showed that more than 20% of individuals with IBS and FD experienced worsening of symptoms, whereas a small percentage noted improvements during the ongoing COVID-19 pandemic; however, most did not show any change in symptoms. Factors that determine the worsening or improvement of symptoms during the COVID-19 pandemic include comorbid psychological illnesses and occupational problems [27].

In the present study, the number of patients with each comorbid disease was small; thus, it is possible that the relationships between the comorbidities and CRP level were not statistically significant. In addition, as this was retrospective study, some data were incomplete [28–35].

It has been reported that a 50% increase in chest X-ray abnormalities within 24–48 hours is considered an early warning indicator of an impending critical illness. CRP level is related to the level of inflammation. Patients with severe pneumonia show elevated CRP levels. It is an important index for the diagnosis and assessment of severe disease. It has been suggested that CRP level is closely related to lung lesions and disease severity in the early stages of COVID-19. In the present study, chest X-ray finding was significantly correlated with CRP level. Similarly, another previous study showed that CRP, which is the laboratory parameter used for assessing acute inflammation, could be elevated in patients with positive chest X-rays and who have severe disease, associated lung damage, and poor prognosis [36–39].

The results of the multivariate analysis showed that hypertension and pneumonia had the most influence on CRP level. A previous study showed that CRP level can predict poor prognosis in patients with hypertension. Inflammation can cause aortic stiffness, leading to disruption of endothelial function. Endothelial dysfunction in older patients and/or patients with hypertension, diabetes, and obesity, combined with vascular damage caused by COVID-19, can lead to severe morbidity and mortality. It has been reported that some patients with COVID-19 who develop pneumonia show changes in chest X-ray images. In addition to older age (≥ 45 years), high CRP level (> 5 mg/dL) and low absolute lymphocyte count (1500 cells/ μ L) are independent risk factors for the development of pneumonia. Several studies have shown that old age, underlying disease, elevated inflammatory parameters, such as CRP level, lactate dehydrogenase level, and low absolute lymphocyte count, are generally associated with poor prognosis in patients with COVID-19 [40–43]. In addition, there are two limitations of this study, namely: the number of confirmed inpatients of COVID-19 at Jakarta Islamic Hospital Sukapura who had comorbidities was only 167 and of each comorbid disease has a small number of patients. Therefore, I hope that the future research can be conducted in several hospitals that represent some areas with higher number of respondents. Furthermore, there are still incomplete data for the deepest analysis because the study was conducted in retrospective method. It was also the other limit of this study. Hence, I assure for the next research, the study should gather the data from primary source.

5. Conclusion

The study was conducted to evaluate the relationship between comorbidities, chest X-ray findings, and CRP level in hospitalised patients with confirmed COVID-19. The results showed that in patients with COVID-19, comorbidities, such as hypertension and diabetes, are correlated with CRP level. The results also showed that chest X-ray findings are significantly correlated with CRP level. Patients with hypertension and pneumonia on chest X-ray tend to have an increased risk for elevated CRP level.

Ethical approval

This research was submitted to the ethics committee of the Faculty of Medicine and Health, Universitas Muhammadiyah Jakarta, Jakarta, Indonesia (No. 185/PE/KE/FKK-UMJ/X/2021) to obtain approval for ethical studies. Written informed consent was obtained from all participants.

Source of funding

No specific funding are available.

Author contribution

M.F, M.H, and E.W. designed the study. M.F, M.H, and E.W. conducted the laboratory analyses. M.F., R.D., A.S., A.R.J., M.R.P, and R.A. reviewed the data, conducted the statistical analyses, and interpreted the results. M.F, M.H, E.W, R.A, R.D, A.S, A.F, and ARJ wrote the first draft of the paper, which all the authors critically reviewed. All the authors read and approved the final manuscript.

Trial registry number

1. Name of the registry: Research Registry
2. Unique Identifying number or registration ID: researchregistry7652
3. Hyperlink to your specific registration (must be publicly accessible and will be checked): <https://www.researchregistry.com/browse-the-registry/#home/registrationdetails/620da1dc74e84d001e6b4ffa/>

Guarantor

Prof. Mochammad Hatta, MD, PhD, Clin Microbiologist (Cons).

Patient consent

None.

Provenance and peer review

Not commissioned, externally peer reviewed.

Data availability

All data generated or analysed during this study are included in this published article.

Declaration of competing interest

The authors declare no conflict of interest, financial or otherwise.

Acknowledgements

We thank the staff of Jakarta Islamic Hospital, Sukapura and the Faculty of Medicine and Health, Universitas Muhammadiyah Jakarta, Jakarta, Indonesia for providing technical support for this study.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.amsu.2022.103553>.

References

- [1] W. Ji, W. Wang, X. Zhao, J. Zai, X. Li, Cross-species transmission of the newly identified coronavirus 2019-nCoV, *J. Med. Virol.* 92 (2020) 433–440, <https://doi.org/10.1002/jmv.25682>.
- [2] Y. Han, H. Yang, The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): a Chinese perspective, *J. Med. Virol.* 92 (2020) 639–644, <https://doi.org/10.1002/jmv.25749>.
- [3] W. Guan, Z. Ni, Y. Hu, W. Liang, C. Ou, J. He, et al., Clinical characteristics of coronavirus disease 2019 in China, *N. Engl. J. Med.* 382 (2020) 1708–1720, <https://doi.org/10.1056/NEJMoa2002032>.
- [4] T.L. Nguyen, A framework for five big V's of big data and organizational culture in firms, in: *Proc - 2018 IEEE Int Conf Big Data, Big Data 2018, 2019*, pp. 411–413. <https://doi.org/10.1109/BigData.2018.8622377>.
- [5] C.M. Petrilli, S.A. Jones, J. Yang, H. Rajagopalan, L. O'Donnell, Y. Chernyak, K. A. Tobin, R.J. Cerfolio, F. Francois, L.I. Horwitz, Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study, *BMJ* 369 (2020) m1966, <https://doi.org/10.1136/bmj.m1966>.
- [6] C. Qin, L. Zhou, Z. Hu, S. Zhang, S. Yang, Y. Tao, C. Xie, K. Ma, K. Shang, W. Wang, D.S. Tian, Dysregulation of immune response in patients with COVID-19 in wuhan, China, *Clin. Inf. Disp.* 71 (2020) 762–768, <https://doi.org/10.1093/cid/ciaa248>.
- [7] G. Wang, C. Wu, Q. Zhang, F. Wu, B. Yu, J. Lv, Y. Li, T. Li, S. Zhang, C. Wu, G. Wu, Y. Zhong, C-reactive protein level may predict the risk of COVID-19 aggravation, *Open Forum Infect. Dis.* 7 (2020), <https://doi.org/10.1093/ofid/ofaa153>.
- [8] L. Marnell, C. Mold, T.W. Du Clos, C-reactive protein: ligands, receptors and role in inflammation, *Clin. Immunol.* 117 (2005) 104–111, <https://doi.org/10.1016/j.clim.2005.08.004>.
- [9] M.L.D. Ndera, N. Supriyatni, A. Rahayu, Faktor komorbid terhadap covid-19 di Puskesmas kota tahun 2020, *J BIOSAINTEK* 3 (2021) 1–9, <https://doi.org/10.52046/biosainstek.v3i2.723>.
- [10] M. Fachri, M. Hatta, M.N. Massi, A. Santoso, T.A. Wikanningtyas, R. Dwiyantri, A. R. Junita, M.R. Primaguna, M. Sabir, The strong correlation between ADAM33 expression and airway inflammation in chronic obstructive pulmonary disease and candidate for biomarker and treatment of COPD, *Sci. Rep.* 11 (2021) 23162, <https://doi.org/10.1038/s41598-021-02615-2>.
- [11] H.Y.F. Wong, H.Y.S. Lam, A.H.T. Fong, S.T. Leung, T.W.Y. Chin, C.S.Y. Lo, M.M. S. Lui, J.C.Y. Lee, K.W.H. Chiu, T.W.H. Chung, E.Y.P. Lee, E.Y.F. Wan, I.F.N. Hung, T.P.W. Lam, M.D. Kuo, M.Y. Ng, Frequency and distribution of chest radiographic findings in patients positive for COVID-19, *Radiology* 296 (2020) E72, <https://doi.org/10.1148/radiol.2020201160>.
- [12] R. Ariza, A.D. Messah, F. Sinaga, A. Wahyudi, S.A. Pratama, I. Annisa, Korelasi gambaran radiografi toraks dengan karakteristik klinis pasien terkonfirmasi covid-19, *Arter J. Ilmu Kesehat.* 2 (2021) 15–22.
- [13] G. Mathew, R. Agha, for the STROCSS Group, StrocSS 2021: strengthening the Reporting of cohort, cross-sectional and case-control studies in Surgery, *Int. J. Surg.* 96 (2021) 106165.
- [14] M. Barry, A.E. AlMohaya, A. AlHijji, L. Akkielah, A. AlRajhi, F. Almajid, A. Alsharidi, F.S. Al-Shahrani, N.H. Alotaibi, A. Alanazi, L. Ghonem, A. Alhtheel, S. Alsubaie, Z.A. Memish, Clinical characteristics and outcome of hospitalized COVID-19 patients in a MERS-CoV endemic area, *J. Epidemiol. Glob. Health.* 10 (2020) 214–221, <https://doi.org/10.2991/jeqh.k.200806.002>.
- [15] Assets, EMG – Transmission Group COVID-19 Risk by Occupation and Workplace, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/965094/s1100-covid-19-risk-by-occupation-workplace.pdf. (Accessed 1 January 2022).
- [16] R. Sharma, M. Agarwal, M. Gupta, S. Somendra, S.K. Saxena, Clinical characteristics and differential clinical diagnosis of novel coronavirus disease 2019 (COVID-19), in: S. Saxena (Ed.), *Coronavirus Disease 2019 (COVID-19). Medical Virology: from Pathogenesis to Disease Control*, Springer, Singapore, 2020, pp. 55–70.
- [17] H. Koh, A.M.C. Moh, E. Yeoh, Y. Lin, S.K.M. Low, S.T. Ooi, S.K. Tan, J.H.X. Lin, C. W.S. Hoong, Diabetes predicts severity of COVID-19 infection in a retrospective cohort: a mediatory role of the inflammatory biomarker C-reactive protein, *J. Med. Virol.* 93 (2021) 3023–3032, <https://doi.org/10.1002/jmv.26837>.
- [18] R.J. Tofano, S.M. Barbalho, M.D. Bechara, K. Quesada, G. C. Mendes, M. Oshiiwa, Hypertension, C reactive protein and metabolic profile: what is the scenario in patients undergoing arteriography? *J. Clin. Diagn. Res.* 11 (2017) BC19–BC23, <https://doi.org/10.7860/JCDR/2017/26595.10456>.
- [19] R. Marlina, M. Hatta, I. Djaharuddin, I. Patellongi, A.D. Susanto, A.A. Islam, M. N. Massi, A. Bukhari, A. Santoso, N.A. Tabri, F. Murtiani, A.R. Junita, A.S. Saleh, R. Dwiyantri, S.R. Pakadang, The changes of HIF-1 α and ICAM-1 expression after miana (coleus scutellarioides [L]) treatment in balb/C mice with Mycobacterium tuberculosis infection, *Biomed. Pharmacol. J.* 15 (2022).
- [20] F. Djannah, M.N. Massi, M. Hatta, A. Bukhari, I. Hasanah, Profile and histopathology features of top three cases of Extra Pulmonary Tuberculosis (EPTB) in West Nusa Tenggara: a retrospective cross-sectional study, *Ann. Med. Surg. (Lond)* 75 (2022) 103318, <https://doi.org/10.1016/j.amsu.2022.103318>.
- [21] R. Shabariah, M. Hatta, I. Idris, A. Santoso, I. Patellongi, T.A.E. Permatasari, Farsida, A.A. Islam, R. Natzir, B. Wahyudin, Emilda Warsinggih, Comparison TLR2 and TLR4 serum levels in children with pulmonary and extrapulmonary tuberculosis with and without a Bacillus Calmette-Guérin (BCG) scar, *J. Clin. Tuberc. Other Mycobac. Dis.* 25 (2021) 100272, <https://doi.org/10.1016/j.jctube.2021.100272>.
- [22] I. Handayani, I. Djaharuddin, R. Natzir, A. Mansyur, A. Ahmad, M. Hatta, R. Agus, I. Patellongi, M. Amin, Y. Widaningsih, H. Halik, N. Hidayah, S.Y. Leman, W. Waworuntu, M.N. Massi, Contribution of NRAMP1 gene expression and protein level in pulmonary and latent TB infection in Indonesia, *J. Appl. Pharmacol. Sci.* 11 (2021) 17–21, <https://doi.org/10.7324/JAPS.2021.110803>.
- [23] H. Agustin, M.N. Massi, I. Djaharuddin, A.D. Susanto, A.A. Islam, M. Hatta, A. Bukhari, N.A. Tabri, A. Santoso, I. Patellongi, Analysis of CD4 and CD8

- expression in multidrug-resistant tuberculosis infection with diabetes mellitus: an experimental study in mice, *Ann. Med. Surg. (Lond)*. 68 (2021) 102596, <https://doi.org/10.1016/j.amsu.2021.102596>.
- [24] R. Marlina, M. Hatta, E. Sridiana, I. Djaharuddin, I. Patellongi, F. Murtian, The effect of miana (coleus scutellarioides [L]) on vascular endothelial growth factor expression in balb/c mice infected with *Mycobacterium tuberculosis*, *biomed, Pharm. J.* 14 (2021) 525–532, <https://doi.org/10.13005/bpj/2154>.
- [25] Farsida, R. Shabariah, M. Hatta, I. Patellongi, Prihantono, M.N. Massi, A.A. Islam, R. Natzir, A.D.B. Febriani, F. Hamid, Fatimah, R. Akaputra, P.A. Savitri, Relationship between expression mRNA gene Treg, Treg, CD4+, and CD8+ protein levels with TST in tuberculosis children: a nested case-control, *Ann. Med. Surg. (Lond)*. 61 (2021) 44–47, <https://doi.org/10.1016/j.amsu.2020.12.011>.
- [26] J. Luo, Y.L. Chen, W. Chen, D.A. Duncan, A. Mentzer, J.C. Knight, G. Ogg, P. Klenerman, I.D. Pavord, L. Xue, Pre-existing asthma as a comorbidity does not modify cytokine responses and severity of COVID-19, *Allergy Asthma Clin. Immunol.* 17 (2021) 1–12, <https://doi.org/10.1186/s13223-021-00569-8>.
- [27] T. Oshima, K.T.H. Siah, T. Yoshimoto, K. Miura, T. Tomita, H. Fukui, H. Miwa, Impacts of the COVID-19 pandemic on functional dyspepsia and irritable bowel syndrome: a population-based survey, *J. Gastroenterol. Hepatol.* (2020) 1–8, <https://doi.org/10.1111/jgh.15346>.
- [28] M. Li, Y. Dong, H. Wang, W. Guo, H. Zhou, Z. Zhang, C. Tian, K. Du, R. Zhu, L. Wang, L. Zhao, H. Fan, S. Luo, D. Hu, Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19, *Nutr. Metabol. Cardiovasc. Dis.* 30 (2020) 1061–1067, <https://doi.org/10.1016/j.numecd.2020.04.013>.
- [29] W.M. Song, J.Y. Zhao, Q.Y. Zhang, S.Q. Liu, X.H. Zhu, Q.Q. An, T.T. Xu, S.J. Li, J. Y. Liu, N.N. Tao, Y. Liu, Y.F. Li, H.C. Li, COVID-19 and tuberculosis coinfection: an overview of case reports/case series and meta-analysis, *Front. Med.* 8 (2021) 657006, <https://doi.org/10.3389/fmed.2021.657006>.
- [30] M. Hatta Farsida, I. Patellongi, Prihantono, R. Shabariyah, R.A. Larasati, A. A. Islam, R. Natzir, M. Nasrum, F. Hamid, A.D. Bahagia, The correlation of Foxp3+ gene and regulatory T cells with scar BCG formation among children with tuberculosis, 100202, *J. Clin. Tuberc. Other Mycobact. Dis.* 21 (2020) 1–7, <https://doi.org/10.1016/j.jctube.2020.100202>.
- [31] F. Umar, M. Hatta, D.R. Husain, R. Dwiyantri, R. Natzir, R.S. Sjahril, A.R. Junita, M. R. Primaguna, Molecular characterization of mutation associated with resistances to first- and second-line tuberculosis drug among tuberculosis patients in Makassar, Indonesia, *J. Taibah Univ. Medical Sci. (Madinah, SA)*. 15 (2020) 54–58, <https://doi.org/10.1016/j.jtumed.2019.12.003>.
- [32] I. Djaharuddin, M. Hatta, N.A. Tabri, E. Muis, S. Safriadi, M.R. Primaguna, Intestinal tuberculosis: case series of three patients, *Respir. Med. Case Rep.* 29 (2020) 100942, <https://doi.org/10.1016/j.rmcr.2019.100942>.
- [33] F. Umar, M. Hatta, D.R. Husain, R. Natzir, R. Dwiyantri, A.R. Junita, M. R. Primaguna, The effect of anti-tuberculosis drugs therapy towards mRNA efflux pump gene expression of Rv1250 in *Mycobacterium tuberculosis* collected from tuberculosis patients, *New Microbes New Infect* 32 (2019) C1–C7, <https://doi.org/10.1016/j.nmni.2019.100609>.
- [34] T.A. Wikanningtyas, M. Hatta, M.N. Massi, I. Pratiwi, M. Fachri, S.S. Santoso, A. Syarifuddin, R. Dwiyantri, R.A. Noviyanthi, Diagnosis of a spectrum of pulmonary tuberculosis at islam hospital Sukapura, Jakarta, Indonesia: a retrospective study of 317 cases, *J. Med. Sci.* 18 (2018) 143–148, <https://doi.org/10.3923/jms.2018.143.148>.
- [35] M. Fachri, M. Hatta, S. Abadi, S.S. Santoso, T.A. Wikanningtyas, A. Syarifuddin, R. Dwiyantri, R.A. Noviyanthi, Comparison of Acid-Fast Bacilli (AFB) smear for *Mycobacterium tuberculosis* on adult Pulmonary tuberculosis (TB) patients with type 2 Diabetes Mellitus (DM) and without type 2 DM, *Respir. Med. Case Rep.* 23 (2018) 158–162, <https://doi.org/10.1016/j.rmcr.2018.02.008>.
- [36] L. Wang, Since January 2020 Elsevier Has Created a COVID-19 Resource Centre with Free Information in English and Mandarin on the Novel Coronavirus COVID-19 . The COVID-19 Resource Centre Is Hosted on Elsevier Connect , the Company's Public News and Information, 2020 January.
- [37] M. Gatti, M. Calandri, M. Barba, A. Biondo, C. Geninatti, S. Gentile, M. Greco, V. Morrone, C. Piatti, A. Santonocito, S. Varello, L. Bergamasco, R. Cavallo, R. Di Stefano, F. Riccardini, A. Bocuzzi, G. Limerutti, A. Veltri, P. Fonio, R. Faletti, Baseline chest X-ray in coronavirus disease 19 (COVID-19) patients: association with clinical and laboratory data, *Radiol. Medica* 125 (2020) 1271–1279, <https://doi.org/10.1007/s11547-020-01272-1>.
- [38] P.F.D. Scheelbeek, A.J.G. Wirix, M. Hatta, R. Usman, M.I. Bakker, Risk factors for poor tuberculosis treatment outcomes in Makassar, Indonesia, *Southeast Asian J. Trop. Med. Publ. Health* 45 (2014) 853–858.
- [39] M. Hatta, A.R. Sultan, N. Tandirogang, Yadi Masjudi, Detection and identification of mycobacterium in sputum from suspected tuberculosis patients, *BMC Res. Notes* 3 (2010) 72, <https://doi.org/10.1186/1756-0500-3-72>.
- [40] J. Amar, N. Touront, A.M. Ciron, C. Pendaries, Interactions between hypertension and inflammatory tone and the effect on blood pressure and outcomes in patients with COVID-19, *J. Clin. Hypertens.* 23 (2021) 238–244, <https://doi.org/10.1111/jch.14137>.
- [41] H.K. Jung, J.Y. Kim, M.S. Lee, J.Y. Lee, J.S. Park, M. Hyun, et al., Characteristics of COVID-19 patients who progress to pneumonia on follow-up chest radiograph: 236 patients from a single isolated cohort in Daegu, South Korea, *Korean J. Radiol.* 21 (2020) 1265–1272, <https://doi.org/10.3348/kjr.2020.0564>.
- [42] M. Hatta, M. Tanaka Ratnawati, J. Ito, T. Shirakawa, M. Kawabata, NRAMP1/SLC11A1 gene polymorphisms and host susceptibility to *Mycobacterium tuberculosis* and leprae in South Sulawesi, Indonesia, *Southeast Asian J. Trop. Med. Publ. Health* 41 (2010) 386–394.
- [43] A.A. Suryanto, J. van den Broek, M. Hatta, R. de Soldenhoff, M.J. van der Werf, Recurrence of tuberculosis in patients treated with single-dose drugs in Combi-packs and fixed-dose combination (4FDC) drugs in South Sulawesi, Indonesia, *Int. J. Tubercul. Lung Dis.* 12 (2008) 174–179.